COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

• Global supportfund for local relief increased to EUR 5.8 million
• Over 100 scientists and 11,000 lab hours committed to COVID-19 research in international consortia, expected to expand
• 10 days paidleave offered to51,000 employees for volunteering
• EUR 580,000 relief fund made availablefor Making More Health communities and social entrepreneurs in India and Kenya
• India makes a ~EUR 150,000 contribution toward local initiatives

Mumbai, 08 April 2020–Boehringer Ingelheim has significantly stepped up its support to the fight against Covid-19. A Global Support Program has been set up to bring more financial relief, protective materials and medicine donations to healthcare institutions and communities in need around the world.

“As a pharmaceuticals company, we feel a strong commitment to offer our help to patients, and to those who help them”, said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “Many of our employees want to participate in the program: we offer support through donations and paid-leave volunteering, engage in significantscientific projects and bring relief to communities in developing regions in Kenya and India, with whom we have a decade-long relationship. All this, plus the drive thatI see with colleagues to ensure continued production ofmedicines, is dedicated to the many, many people who suffer from COVID-19. Our thoughts are with them and their loved ones.”

According to Sharad Tyagi, Managing Director, MD, Boehringer Ingelheim India, “During this unprecedented crisis, Boehringer Ingelheim India joins hand for helping in the common cause, by extending aid for local initiatives. We have presently made a contribution of ~EUR 150,000 supporting various local initiatives. This includes aid via Americares India Foundation to support Brihanmumbai Municipal Corporation (BMC) for setting up COVID-19 quarantine centers and donation of 1,000 PPE’s, procuring N95 masks from China for distribution to hospitals and providing 5,000 3 ply masks for HCP’s to BMC. We have also made a significant contribution to the PM Cares Fund. We are committed to supporting the government in their efforts to contain the pandemic.”

Boehringer Ingelheim initially started a EUR 1 million donations program in January for affected regions in China. With the Corona virus spreading to become a global pandemic,efforts to provide relief and scientific support grew strongly these past few weeks. This ultimately resulted in a Global Support Program with four focus areas:

1. Donations
Boehringer Ingelheim hasmade available EUR 5.8 million forfinancial and in-kind donations for local emergency aid across its markets. This includes, for example, protective masks, disinfectants, inhalers and medicines.The company is also working with local organizations that use financial and medicine donations to organize help for patientsin their communities.

2. Research for COVID-19 Therapies
Since January, a growing team of currently more than 100 highly engaged Boehringer Ingelheim scientists from all areas of research and development (R&D) have contributed to projects aimed at finding potential treatment solutions for COVID-19. “All of us are thinking about how we can find new ways to tackle this virus. This has led to a broad program pursuing many approaches in parallel”, says Dr Cyrille Kuhn, Executive Director Research, who leads Boehringer Ingelheim’s COVID-19 efforts since January.

Moreover, an increasing number of collaboration partners and service providers is bolstering the team’s efforts. Most of the projects are part of larger collaborative efforts with academia, biotech and other pharma companies. Among them is a call by the Innovative Medicines Initiative of the EU (IMI), to which Boehringer Ingelheim is planning to commit in excess of 11,000 work hours in R&D. The company also joined the Bill & Melinda Gates Foundation COVID-19 Therapeutic Accelerator.
The company also joined the Bill & Melinda Gates Foundation COVID-19 Therapeutic Accelerator. In addition, Boehringer Ingelheim supports scientists worldwide with its open innovation portal opnMe.com, which offers 6 anti-viral compounds out of 43 high quality pharmacological tool compounds at no cost for testing of research hypotheses.

As this work evolves, the company will commit further experts from multiple disciplines, as well as increased lab capacity.

3. Volunteering
In many communities, helping hands fromvolunteers, for example with a medical or nursingbackground, are urgently needed. Boehringer Ingelheim offersall of its 51,000 employees the opportunityto take up to 10 days of paid leave to joinapproved external organizations as a volunteer to bring COVID-19 relief.Employees who are unable to perform their work on-site or from home, are given the opportunity to volunteer for longer while paid their regular salaries, until they can resume their work.

4. Making More Health relief fund
An EUR 580,000relief fund has been launched to support the global Making More Health (MMH) network of social entrepreneurs in Kenya and India (Coimbatore), as well as the communities in which they live and work.
The fund will help social enterprises and their activities to sustain a longer period of low economic activity and will invest in social entrepreneurial ideas that can help reduce the risk of the Corona virus spreading.

“Especially in times like these Social Entrepreneurs around the world are well placed to leverage their proximity to those in needs”, said Jean Scheftsik de Szolnok, member of the Board of Managing Directors and one of the founders of the MMH movement. “MMH communities such as self-help groups in India or people suffering from albinism in Kenya, have started to produce soap and at the same time education programs on hygiene awareness in their neighborhoods.”Over the past yearsmore than 750 students at the MMH school and some 1,000 families in farmer cooperatives have been trained in hygiene and soap production in Kenya and India.

Boehringer Ingelheim is committed to the global community and to the well-being of people and animals. As a research-driven company, it started its support activities in January and will continue to do what it can to deliver a meaningful contribution in the fight against COVID-19. The company continues to support healthcare systems by reliably supplying drugs and through our research.

More information on the variousCOVID-19 initiatives under the Global Support Program are available under:
https://www.boehringer-ingelheim.com/covid-19

Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Our significant investment in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.